Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Biologics-induced autoimmune diseases.
Insight into the mechanism of laquinimod action.
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Teriflunomide for multiple sclerosis.
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1.
ARESTIN®
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
Biogen Idec receives notification of PDUFA date extension for PLEGRIDY™ (peginterferon beta-1a)
Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study.
Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
β-Amyloid: Enemy or Remedy?
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Pharmacodynamics of Dimethyl Fumarate are Tissue-specific and Involve NRF2-dependent and -independent Mechanisms.
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis

Pages